Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (31-40 of 140) with videos related to

Pageof 14
Sort By:
HIV Clinical Trials|May 29, 2002
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 studyMartyn French, Janaki Amin, Norman Roth, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2003
Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testingChris Birch, Tracey Middleton, Gillian Hales, et al.
Plos One|June 22, 2012
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudineHila Haskelberg, Jennifer F Hoy, Janaki Amin, et al.
European Journal of Medicinal Chemistry|November 16, 2017
Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effectsLeah K Forsberg, Mercy Anyika, Zhenyuan You, et al.
HIV Medicine|February 26, 2015
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial, Jens Lundgren, Abdel Babiker, et al.
AIDS (London, England)|September 24, 2009
Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trialTim R H Read, Dianne Carey, Patrick Mallon, et al.
AIDS (London, England)|November 21, 2007
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infectionHandan Wand, Alexandra Calmy, Dianne L Carey, et al.
Plos One|March 5, 2013
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaKaren Schneider, Chidi Nwizu, Richard Kaplan, et al.
AIDS Research and Human Retroviruses|June 22, 2010
A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infectionSarah L Pett, John Zaunders, Michelle Bailey, et al.
AIDS (London, England)|July 17, 2010
Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgammaRIIa genotypeMartyn A French, Sara Tanaskovic, Matthew G Law, et al.
Pageof 14

Showing results (31-40 of 140) with videos related to

Sort By:
Pageof 14
HIV Clinical Trials|May 29, 2002
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 studyMartyn French, Janaki Amin, Norman Roth, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2003
Limited evolution of HIV antiretroviral drug resistance-associated mutations during the performance of drug resistance testingChris Birch, Tracey Middleton, Gillian Hales, et al.
Plos One|June 22, 2012
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudineHila Haskelberg, Jennifer F Hoy, Janaki Amin, et al.
European Journal of Medicinal Chemistry|November 16, 2017
Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effectsLeah K Forsberg, Mercy Anyika, Zhenyuan You, et al.
HIV Medicine|February 26, 2015
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial, Jens Lundgren, Abdel Babiker, et al.
AIDS (London, England)|September 24, 2009
Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trialTim R H Read, Dianne Carey, Patrick Mallon, et al.
AIDS (London, England)|November 21, 2007
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infectionHandan Wand, Alexandra Calmy, Dianne L Carey, et al.
Plos One|March 5, 2013
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaKaren Schneider, Chidi Nwizu, Richard Kaplan, et al.
AIDS Research and Human Retroviruses|June 22, 2010
A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5+CD4+ and CCR5+CD8+ T cell numbers in chronic HIV infectionSarah L Pett, John Zaunders, Michelle Bailey, et al.
AIDS (London, England)|July 17, 2010
Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgammaRIIa genotypeMartyn A French, Sara Tanaskovic, Matthew G Law, et al.
Pageof 14